Carlsmed's Inflection Point Came With a DRG Code — and a New CFO
Q3 revenue rose 65% and guidance went up, but the 'inflection' is an adjusted construct built on $2.8M of one-timers and a finance bench rebuilt weeks before the print.
CARL · Earnings Call · 2026-11-10
An inflection point with a start date
For two quarters Carlsmed discussed the CMS inpatient payment rule the way you discuss weather three days out — real, directional, not yet actionable. Asked in May about the proposed IPPS rule, Michael Cordonnier declined to speculate: “It is early days, and it is a preliminary rule. We are really holding off on those discussions until the final rule goes into place.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 The rule went into place on October 1, 2026, collapsing eleven lumbar MS-DRGs into three codes (523, 524, 525), and on this call the same executive had something he could actually measure: “We did see an uptick in new hospital acquisitions going on contract exiting Q3 and continuing through Q4.” — Michael Cordonnier · 2026-11-10 That is the news in this quarter, and it is why inflection point — a phrase absent from this company's keyword stack through the spring — now sits near the top of it beside DRG codes. The operating numbers behind the framing are genuinely strong: revenue of $21.6 million, up 65% from $13.1 million, procedure volume up 76%, and the trained surgeon user base up more than 60% year-over-year. Full-year guidance went from $74–78 million to $78–80 million, more than 56% growth at the midpoint. What makes this more than a beat-and-raise is that the reimbursement change is durable rather than a one-year add-on payment, and it arrives at the moment the company is pushing two new procedures through the same technology platform.Two launches, one platform, one number that matters
The posterior bi-lateral lumbar system launched in mid-October and addresses roughly 30,000 procedures, about 7% of US lumbar fusions. The corra cervical plating system ships within weeks, and roughly 60% of ACDF procedures use fixation plates — meaning the cervical franchise stops being a stand-alone interbody story and becomes a full-procedure story. This is the lumbar procedure-to-cervical flywheel management has been promising since the December cervical launch, and it is now compounding faster than the model: “cervical mix as a percentage of the total in the third quarter was 12%.” — Richard Heppenstall · 2026-11-10 Recall what they told you in May: “high single-digit to low double-digit percent contribution of revenue from cervical in the total plan for the company looks about right.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 Twelve percent in Q3, with another ~3 points of mix gain over the last few quarters, is a guidance miss in the good direction — the first time this management team has materially beaten its own mix assumption. The commercial launch cadence is the tell: this is a company adding procedures to a shared digital production and planning stack rather than building new factories. Gross margin of 77.3% (up ~140bps) on a capital-light model is the proof: gross margin has climbed from 75% at the 2024 launch to 77.3%, with the two-year move worth roughly +2 points.The bill for the inflection
Here the story gets less tidy. G&A came in at $10 million against $4.9 million, and $2.3 million of that is executive transition costs plus the resolution of certain legal matters — two phrases that did not exist in this company's earnings vocabulary until this quarter and now rank as top-25 keywords in it. A further $0.5 million of transition cost landed, oddly, inside R&D. Add the personnel news — Rich Heppenstall arriving as CFO from ZimVie, Jeff Bertolini promoted to COO, and an ex-Intuitive Surgical AI chief installed in a newly created product role on October 1 — and you have three senior seats changed within about six weeks of the print. That is not scandal; it is a company declaring it is entering a different operating phase. But it means the quarter's headline profitability claim needs the footnote.True on an adjusted basis: adjusted EBITDA improved to −$7.3 million from −$8.2 million. On GAAP, operating income was still −$11 million in the last reported period with a −58% operating margin, and the loss has widened as revenue has grown. The bridge is stock compensation: the SBC add-back is running up more than 7x year-over-year, and Q4 guidance of $2.75–3 million implies SBC alone near 14% of guided quarterly revenue. SG&A, meanwhile, is up 128% year-over-year versus revenue's 57%. Operating leverage, in other words, arrives only after you exclude roughly $2.8 million of items the company chose to exclude. Cash is not the issue: $80.3 million against $9 million of quarterly burn buys time, and the $15.6 million drawn on a $50 million facility maturing in 2030 is genuinely cheap, non-dilutive runway.Q3 was the first quarter where our sales growth and strong gross margins generated positive operating leverage on our profitability.